Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Eli Lilly Drug Patent Portfolio

Eli Lilly owns 13 orange book drugs protected by 57 US patents with Prozac having the least patent protection, holding only 1 patent. And Retevmo with maximum patent protection, holding 12 patents. Given below is the list of Eli Lilly's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12295987 Method of using a GIP/GLP1 co-agonist for diabetes 30 Dec, 2041
Active
US12071423 Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate 06 Jul, 2040
Active
US12343382 22 Jul, 2039
Active
US12453758 22 Jul, 2039
Active
US10654866 11 Jul, 2039
Active
US11117902 11 Jul, 2039
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
Active
US12453755 14 Jun, 2039
Active
US12453756 14 Jun, 2039
Active
US11918623 GIP/GLP1 agonist compositions 14 Jun, 2039
Active
US10584124 10 Apr, 2039
Active
US10786489 10 Apr, 2039
Active
US12138250 10 Apr, 2039
Active
US10584124 Crystalline forms 10 Oct, 2038
Active
US10786489 Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile 10 Oct, 2038
Active
US12138250 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 10 Oct, 2038
Active
US10112942 10 Apr, 2038
Active
US10137124 10 Apr, 2038
Active
US10172851 10 Apr, 2038
Active
US11053214 Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists 05 Dec, 2037
Active
US10112942 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
Active
US10137124 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
Active
US10172851 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
Active
US9474780 GIP and GLP-1 co-agonist compounds 05 Jan, 2036
Active
US11045474 Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections 30 Nov, 2032
Active
US9089574 Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections 30 Nov, 2032
Active
US8158616 Azetidine and cyclobutane derivatives as JAK inhibitors 31 May, 2032
Active
US11806555 Methods for treating hair loss disorders 02 Nov, 2031
Active
US9737469 Methods for treating hair loss disorders 02 Nov, 2031
Active
US7855211 Protein kinase inhibitors 28 Sep, 2031
Active
US9402957 Automatic injection device with delay mechanism including dual functioning biasing member 29 Jun, 2031
Active
US8734394 Automatic injection device with delay mechanism including dual functioning biasing member 24 Feb, 2031
Active
US12257246 Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide 07 Jul, 2030
Active
US8420629 Azetidine and cyclobutane derivatives as JAK inhibitors 10 Mar, 2029
Active
US7423050 Pyridinoylpiperidines as 5-HT1F agonists 17 Feb, 2028
Active
US8435944 Method and composition for transdermal drug delivery 27 Sep, 2027
Active
US8419307 Spreading implement 26 Feb, 2027
Active
US8807861 Spreading implement 26 Feb, 2027
Active
US9289586 Spreading implement 26 Feb, 2027
Active
US8993520 Method and composition for transdermal drug delivery 02 Jun, 2026
Active
US9180194 Method and composition for transdermal drug delivery 02 Jun, 2026
Active
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024 Expired
US8784878 Transdermal delivery rate control using amorphous pharmaceutical compositions 13 Jul, 2023 Expired
US8748459 Pyridinoylpiperidines as 5-HT1F agonists 27 Mar, 2023 Expired
US6821975 Beta-carboline drug products 19 May, 2021 Expired
US6821975 Beta-carboline drug products 19 Nov, 2020 Expired
US7182958 β-carboline pharmaceutical compositions 26 Oct, 2020 Expired
US7182958 β-carboline pharmaceutical compositions 26 Apr, 2020 Expired
US6034054 Stable insulin formulations 11 Jun, 2018 Expired
US6551992 Stable insulin formulations 11 Jun, 2018 Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 May, 2018 Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 Nov, 2017 Expired
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017 Expired
US6299900 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017 Expired
US6818226 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017 Expired
US6923983 Transdermal delivery of hormones 19 Feb, 2017 Expired
US8071075 Dermal penetration enhancers and drug delivery systems involving the same 19 Feb, 2017 Expired


Given below is the list of recent legal activities going on the following drug patents of Eli Lilly.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 21 Mar, 2024 US9474780
Payment of Maintenance Fee, 8th Year, Large Entity 21 Mar, 2024 US9474780
Patent eGrant Notification 05 Mar, 2024 US11918623
Recordation of Patent eGrant 05 Mar, 2024 US11918623
Email Notification
Critical
05 Mar, 2024 US11918623
Mail Patent eGrant Notification 05 Mar, 2024 US11918623
Recordation of Patent eGrant 05 Mar, 2024 US11918623
Patent Issue Date Used in PTA Calculation
Critical
05 Mar, 2024 US11918623
Mail Patent eGrant Notification 05 Mar, 2024 US11918623
Patent eGrant Notification 05 Mar, 2024 US11918623
Patent Issue Date Used in PTA Calculation
Critical
05 Mar, 2024 US11918623
Recordation of Patent Grant Mailed
Critical
05 Mar, 2024 US11918623
Recordation of Patent Grant Mailed
Critical
05 Mar, 2024 US11918623
Email Notification
Critical
05 Mar, 2024 US11918623
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9474780


Eli Lilly's Drug Patent Litigations

Eli Lilly's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 13, 2015, against patent number US7182958. The petitioner Actelion Pharmaceuticals Ltd, challenged the validity of this patent, with ICOS Corporation as the respondent. Click below to track the latest information on how companies are challenging Eli Lilly's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9474780 May, 2025 Pending Eli Lilly & Co. Empower Clinic Services, LLC. (d/b/a Empower Pharmacy)
US9474780 August, 2025 Pending Eli Lilly & Co. BPI Labs, LLC et al.
US6821975 January, 2015 Final Written Decision
(03 Aug, 2016)
ICOS Corporation et al. Actelion Pharmaceuticals Ltd
US6821975 January, 2015 FWD Entered
(03 Aug, 2016)
ICOS Corporation Actelion Pharmaceuticals Ltd
US7182958 January, 2015 Final Written Decision
(03 Aug, 2016)
ICOS Corporation et al. Actelion Pharmaceuticals Ltd
US7182958 January, 2015 FWD Entered
(03 Aug, 2016)
ICOS Corporation Actelion Pharmaceuticals Ltd


Eli Lilly Drug Patents' Oppositions Filed in EPO

Eli Lilly drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 26, 2017, by Müller Fottner Steinecke Rechtsanwalts- Und Patentanwaltspartnerschaft Mbb. This opposition was filed on patent number EP03729716A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11838771A Apr, 2020 Concert Pharmaceuticals, Inc. Granted and Under Opposition
EP06741180A Aug, 2017 Müller Fottner Steinecke Rechtsanwalts- und Patentanwaltspartnerschaft mbB Revoked
EP03729716A Apr, 2017 Müller Fottner Steinecke Rechtsanwalts- und Patentanwaltspartnerschaft mbB Revoked


Eli Lilly's Family Patents

Eli Lilly drugs have patent protection in a total of 55 countries. It's US patent count contributes only to 19.0% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents





Clinical Trials

Recent Clinical Trials by Eli Lilly:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Eli Lilly and Company NA RECRUITING
(Sep, 2024)
PHASE2
A Study of LY3841136 in Overweight and Obese Participants Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Sep, 2024)
PHASE1
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Eli Lilly and Company NA COMPLETED
(Aug, 2024)
PHASE4
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity Eli Lilly and Company Regeneron Pharmaceuticals RECRUITING
(Aug, 2024)
PHASE2
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial Eli Lilly and Company NA COMPLETED
(Jul, 2024)
PHASE3
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul, 2024)
PHASE3
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Eli Lilly and Company NA COMPLETED
(Apr, 2024)
PHASE2
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes Eli Lilly and Company NA COMPLETED
(Jun, 2022)
PHASE1
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Eli Lilly and Company NA COMPLETED
(Jan, 2022)
PHASE3


Eli Lilly Drug List

Given below is the complete list of Eli Lilly's drugs and the patents protecting them.


1. Adcirca

Adcirca is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6821975
(Pediatric)
Beta-carboline drug products 19 May, 2021
(4 years ago)
Expired
US6821975 Beta-carboline drug products 19 Nov, 2020
(5 years ago)
Expired
US7182958
(Pediatric)
β-carboline pharmaceutical compositions 26 Oct, 2020
(5 years ago)
Expired
US7182958 β-carboline pharmaceutical compositions 26 Apr, 2020
(5 years ago)
Expired
US5859006
(Pediatric)
Tetracyclic derivatives; process of preparation and use 21 May, 2018
(7 years ago)
Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 Nov, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adcirca's drug page


2. Axiron

Axiron is protected by 11 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8435944 Method and composition for transdermal drug delivery 27 Sep, 2027
(1 year, 8 months from now)
Active
US8419307 Spreading implement 26 Feb, 2027
(1 year, 1 month from now)
Active
US8807861 Spreading implement 26 Feb, 2027
(1 year, 1 month from now)
Active
US9289586 Spreading implement 26 Feb, 2027
(1 year, 1 month from now)
Active
US8993520 Method and composition for transdermal drug delivery 02 Jun, 2026
(4 months from now)
Active
US9180194 Method and composition for transdermal drug delivery 02 Jun, 2026
(4 months from now)
Active
US8784878 Transdermal delivery rate control using amorphous pharmaceutical compositions 13 Jul, 2023
(2 years ago)
Expired
US6299900 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017
(8 years ago)
Expired
US6818226 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017
(8 years ago)
Expired
US6923983 Transdermal delivery of hormones 19 Feb, 2017
(8 years ago)
Expired
US8071075 Dermal penetration enhancers and drug delivery systems involving the same 19 Feb, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Axiron's drug page


3. Humalog Kwikpen

Humalog Kwikpen is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024
(1 year, 4 months ago)
Expired
US6034054 Stable insulin formulations 11 Jun, 2018
(7 years ago)
Expired
US6551992 Stable insulin formulations 11 Jun, 2018
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Kwikpen's drug page


4. Inluriyo

Inluriyo is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10654866 11 Jul, 2039
(13 years from now)
Active
US11117902 11 Jul, 2039
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inluriyo's drug page


5. Mounjaro

Mounjaro is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12295987 Method of using a GIP/GLP1 co-agonist for diabetes 30 Dec, 2041
(15 years from now)
Active
US12343382 22 Jul, 2039
(13 years from now)
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(13 years from now)
Active
US12453755 14 Jun, 2039
(13 years from now)
Active
US12453756 14 Jun, 2039
(13 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 05 Jan, 2036
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mounjaro's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Mounjaro (autoinjector)

Mounjaro (autoinjector) is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12295987 Method of using a GIP/GLP1 co-agonist for diabetes 30 Dec, 2041
(15 years from now)
Active
US12343382 22 Jul, 2039
(13 years from now)
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(13 years from now)
Active
US12453755 14 Jun, 2039
(13 years from now)
Active
US12453756 14 Jun, 2039
(13 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 05 Jan, 2036
(9 years from now)
Active
US9402957 Automatic injection device with delay mechanism including dual functioning biasing member 29 Jun, 2031
(5 years from now)
Active
US8734394 Automatic injection device with delay mechanism including dual functioning biasing member 24 Feb, 2031
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mounjaro (autoinjector)'s drug page


7. Olumiant

Olumiant is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11045474 Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections 30 Nov, 2032
(6 years from now)
Active
US9089574 Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections 30 Nov, 2032
(6 years from now)
Active
US8158616 Azetidine and cyclobutane derivatives as JAK inhibitors 31 May, 2032
(6 years from now)
Active
US11806555 Methods for treating hair loss disorders 02 Nov, 2031
(5 years from now)
Active
US9737469 Methods for treating hair loss disorders 02 Nov, 2031
(5 years from now)
Active
US8420629 Azetidine and cyclobutane derivatives as JAK inhibitors 10 Mar, 2029
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olumiant's drug page


8. Prozac

Prozac is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prozac's drug page


9. Retevmo

Retevmo is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10584124
(Pediatric)
10 Apr, 2039
(13 years from now)
Active
US10786489
(Pediatric)
10 Apr, 2039
(13 years from now)
Active
US12138250
(Pediatric)
10 Apr, 2039
(13 years from now)
Active
US10584124 Crystalline forms 10 Oct, 2038
(12 years from now)
Active
US10786489 Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile 10 Oct, 2038
(12 years from now)
Active
US12138250 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 10 Oct, 2038
(12 years from now)
Active
US10112942
(Pediatric)
10 Apr, 2038
(12 years from now)
Active
US10137124
(Pediatric)
10 Apr, 2038
(12 years from now)
Active
US10172851
(Pediatric)
10 Apr, 2038
(12 years from now)
Active
US10112942 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
(11 years from now)
Active
US10137124 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
(11 years from now)
Active
US10172851 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Retevmo's drug page


10. Reyvow

Reyvow is protected by 5 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12071423 Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate 06 Jul, 2040
(14 years from now)
Active
US11053214 Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists 05 Dec, 2037
(11 years from now)
Active
US12257246 Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide 07 Jul, 2030
(4 years from now)
Active
US7423050 Pyridinoylpiperidines as 5-HT1F agonists 17 Feb, 2028
(2 years from now)
Active
US8748459 Pyridinoylpiperidines as 5-HT1F agonists 27 Mar, 2023
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Reyvow's drug page


11. Verzenio

Verzenio is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7855211 Protein kinase inhibitors 28 Sep, 2031
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Verzenio's drug page


12. Zepbound

Zepbound is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12343382 22 Jul, 2039
(13 years from now)
Active
US12453758 22 Jul, 2039
(13 years from now)
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(13 years from now)
Active
US11918623 GIP/GLP1 agonist compositions 14 Jun, 2039
(13 years from now)
Active
US12453756 14 Jun, 2039
(13 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 05 Jan, 2036
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepbound's drug page


13. Zepbound (autoinjector)

Zepbound (autoinjector) is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12343382 22 Jul, 2039
(13 years from now)
Active
US12453758 22 Jul, 2039
(13 years from now)
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(13 years from now)
Active
US11918623 GIP/GLP1 agonist compositions 14 Jun, 2039
(13 years from now)
Active
US12453756 14 Jun, 2039
(13 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 05 Jan, 2036
(9 years from now)
Active
US9402957 Automatic injection device with delay mechanism including dual functioning biasing member 29 Jun, 2031
(5 years from now)
Active
US8734394 Automatic injection device with delay mechanism including dual functioning biasing member 24 Feb, 2031
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepbound (autoinjector)'s drug page